ABSTRACT
<p><b>Objective</b>To investigate the effect and safety of oral Tonglin Powder in the treatment of benign prostatic hyperplasia (BPH).</p><p><b>METHODS</b>We conducted a randomized controlled study on 100 BPH patients, aged 40－85 years, treated with Tonglin Powder (treatment group, n=50) or terazosin (control group, n=50), all for 3 months. Then we obtained the International Prostate Symptom Score (IPSS), quality of life score (QoL), prostate volume, postvoid residual urine volume (PVR), urine routine indexes, and liver and kidney function indexes from the patients and compared them between the two groups before and after treatment.</p><p><b>RESULTS</b>The baseline data of the patients in the treatment and control groups were as follows, IPSS (22.24±7.33) vs (21.40±8.24), QoL 4 (2－6) vs 4 (2－6), prostate length 45 (30－65) vs 45 (39－65) mm, prostate width 35 (21－54) vs 36 (26－57) mm, and PVR 10 (5－100) vs 10 (10－100) ml, none with statistically significant difference between the two groups (P>0.05). After treatment, the patients of the treatment group, in comparison with those of the control, showed remarkable decreases in IPSS (11.60±6.49 vs 15.38±7.34, P=0.008) and QoL (2 ［0－5］ vs 3 ［1－6］, P=0.01). No statistically significant differences were observed between the treatment and control groups in prostate length (47 ［38－67］ vs 47.5 ［38－67］ mm), prostate width (36 ［26－57］ vs 36.5 ［31－57］ mm), and PVR (10 ［8－100］ vs 10 ［8－70］ ml) (P>0.05). The Nimodipine method of evaluation showed that the excellence rate of therapeutic effectiveness was significantly higher in the treatment than in the control group (40% vs 8%, P<0.001), and so was the total effectiveness rate (82% vs 64%, P=0.043).</p><p><b>CONCLUSIONS</b>Tonglin Powder can effectively improve the symptoms of BPH, such as difficult urination, and hence the patient's quality of life.</p>
ABSTRACT
<p><b>OBJECTIVE</b>To study the effect of Hath1 gene transfer on the proliferation of colonic cancer cells in vitro.</p><p><b>METHODS</b>The recombinant plasmid pcDNA3.1(+)-Hath1 was transfected into HT29 colonic cancer cells, and 3 positive cell clones were randomly selected to test the levels of Hath1 mRNA, Muc2 mRNA, Hath1, Muc2, cyclin D1 and p27 by quantitative real-time RT-PCR and Western blotting. The proliferation of the transfected HT29 cells was observed by means of colony formation assay and xenograft growth in nude mice.</p><p><b>RESULTS</b>Hath1 significantly down-regulated of cyclin D1 and up-regulate of p27 expressions and inhibited the proliferation of HT29 cells.</p><p><b>CONCLUSION</b>Hath1 gene may be an anti-oncogene in colon carcinogenesis.</p>
Subject(s)
Animals , Humans , Male , Mice , Basic Helix-Loop-Helix Transcription Factors , Genetics , Metabolism , Cell Line, Tumor , Cell Proliferation , Colonic Neoplasms , Pathology , Cyclin D1 , Genetics , Metabolism , Gene Transfer Techniques , Mice, Inbred BALB C , Mice, Nude , Mucin-2 , Genetics , Metabolism , Proliferating Cell Nuclear Antigen , Genetics , Metabolism , RNA, Messenger , GeneticsABSTRACT
<p><b>OBJECTIVE</b>To retrospectively analyze the experiences and results of the treatment on 62 patients with primary varicose of lower extremities with endovenous laser.</p><p><b>METHODS</b>All patients were treated with endovenous laser. The laser treatment could begin when the fiber withdraw with 1 cm/2 s. The laser power was 10 - 12 w with the laser pulse duration and the interval 1 second respectively.</p><p><b>RESULTS</b>The duration of follow-up varied from 2 months to 8 months. After endovenous treatment, the varicose veins and edema disappeared in all cases. The itching and uncomfortable feeling was dissipated. No morphine-like analgesic has been used and no serious complications occurred.</p><p><b>CONCLUSION</b>Endovenous laser treatment of primary varicose of lower extremities is a safe and effective technique.</p>